Demystifying Brain Penetration in Central Nervous System Drug Discovery
Top Cited Papers
- 17 October 2012
- journal article
- perspective
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 56 (1), 2-12
- https://doi.org/10.1021/jm301297f
Abstract
This Perspective provides important concepts about the blood–brain barrier (BBB) in drug discovery and how they should be applied effectively in designing successful CNS drugs. Key parameters for brain penetration are discussed, including unbound brain concentration, unbound brain-to-plasma ratio, BBB permeability, fraction unbound in brain and plasma, and transporters. Results from a retrospective analysis of 32 Pfizer CNS clinical drug candidates are described. Frequently encountered misconceptions about brain penetration in drug discovery programs are clarified. Strategies and guidance are provided to enhance or minimize brain exposure for CNS or peripheral targets, respectively. Recommendations for screening methodologies and a cascade in assessing brain penetration potential are presented.Keywords
This publication has 58 references indexed in Scilit:
- Quantitative Pharmacokinetic/Pharmacodynamic Analyses Suggest That the 129/SVE Mouse Is a Suitable Preclinical Pharmacology Model for Identifying Small-Molecule γ-Secretase InhibitorsJournal of Pharmacology and Experimental Therapeutics, 2011
- The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discoveryNature Reviews Drug Discovery, 2010
- Membrane transporters in drug developmentNature Reviews Drug Discovery, 2010
- Structure and function of the blood–brain barrierNeurobiology of Disease, 2010
- Unbound Drug Concentration in Brain Homogenate and Cerebral Spinal Fluid at Steady State as a Surrogate for Unbound Concentration in Brain Interstitial FluidDrug Metabolism and Disposition, 2008
- Strategies to assess blood–brain barrier penetrationExpert Opinion on Drug Discovery, 2008
- THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODELDrug Metabolism and Disposition, 2004
- RELATIONSHIP BETWEEN EXPOSURE AND NONSPECIFIC BINDING OF THIRTY-THREE CENTRAL NERVOUS SYSTEM DRUGS IN MICEDrug Metabolism and Disposition, 2004
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004
- Crossing the blood–brain barrier: are we getting it right?Drug Discovery Today, 2001